GGHC
KERX

Gilder Gagnon Howe & Co’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-18,631
Closed -$317K – 329
2014
Q1 		$317K Sell
18,631
-122
-0.7% -$1.84K ﹤0.01% 238
2013
Q4 		$243K Sell
18,753
-2,520
-12% -$30.1K ﹤0.01% 236
2013
Q3 		$215K Sell
21,273
-1,177,148
-98% -$10.5M ﹤0.01% 237
2013
Q2 		$8.95M Buy
+1,198,421
New +$9.36M 0.17% 107

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Gilder Gagnon Howe & Co's KERX Position: Q2 2014 in Review

Gilder Gagnon Howe & Co sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2014, closing a stake of 18,631 shares — an estimated $317K sold.

Gilder Gagnon Howe & Co first reported a position in KERX in Q2 2013 and held it in 4 quarters. The position peaked at $8.95M in Q2 2013. 135 funds tracked by Wall St. Rank hold KERX as of Q2 2014.

  • Gilder Gagnon Howe & Co reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 18,631 Keryx Biopharmaceuticals Inc shares in Q2 2014, an estimated $317K.
  • Gilder Gagnon Howe & Co first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 4 quarters.
  • Gilder Gagnon Howe & Co's Keryx Biopharmaceuticals Inc position peaked at $8.95M in Q2 2013.
  • 135 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2014.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2014, filed 1 Aug 2014.